Abigail L. Jenkins - 19 Oct 2023 Form 4/A - Amendment Insider Report for Gamida Cell Ltd.

Role
President and CEO, Director
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 Oct 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Oct 2023, 16:34:06 UTC
Date Of Original Report
20 Sep 2022
Previous filing
04 Oct 2022
Next filing
26 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMDA Ordinary Shares Award $0 +250,000 +1550% $0.000000 266,129 19 Oct 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMDA Employee Share Option (Right to Buy) Award $0 +1,000,000 $0.000000 1,000,000 19 Oct 2023 Ordinary Shares 1,000,000 $2.22 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on September 19, 2022, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023.
F2 Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of September 19, 2023 and September 19, 2024, respectively, and with respect to 34% of the RSUs, on September 19, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
F3 The option grant was approved by the Board of Directors of the Issuer on September 19, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.
F4 One fourth (1/4th) of the shares subject to the option award vested on September 19, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

This amendment is being filed solely to correct the transaction dates to October 19, 2023 and to correct the expiration date of the option grant to October 18, 2033.